Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP ) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study Meeting Abstract

  

Authors:	Dietrich, S.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J.; Herbaux, C.; Burke, J. M.; Matasar, M.; Rai, S.; Izutsu, K.; Mehta-Shah, N.; Oberic, L.; Chauchet, A.; Jurczak, W.; Song, Y. Q.; Greil, R.; Mykhalska, L.; Burgués, J. M. B.; Cheung, M. C.; Pinto, A.; Shin, H. J.; Hapgood, G.; Munhoz, E.; Salles, G.
Abstract Title:	Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP ) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study
Meeting Title:	2022 Deutscher Krebskongress. Krebsmedizin: Schnittstellen zwischen Innovation und Versorgung
Journal Title:	Oncology Research and Treatment
Volume:	45
Issue:	Suppl. 3
Meeting Dates:	2022 Nov 13-16
Meeting Location:	Berlin, Germany
ISSN:	2296-5270
Publisher:	S. Karger AG
Date Published:	2022-11-01
Start Page:	164
Language:	English
ACCESSION:	WOS:000883051700384
PROVIDER:	wos
DOI:	10.1159/000521004
Notes:	Meeting Abstract: 891 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/202435